Arna Assist


We believe that people who need our medicines should be able to get them. That’s why we offer eligible patients access to our BRONCHITOL Patient Assistance Program or our BRONCHITOL $0 Copay Assistance Program.

Arna-logo1

Service Request and Prescription

If you think BRONCHITOL may be right for you, take the first step by speaking with your healthcare provider. This guide includes a few questions you may want to ask to help start the conversation.

Arna Patient Assistance Overview

BRONCHITOL Patient Assistance Program (PAP) eligibility requirements are available for qualified patients who are uninsured or underinsured and cannot afford their medication (based on percentage of the Federal Poverty Level). Patient must have commercial insurance; be a legal United States resident; and be enrolled in Arna Assist. Underinsured means the patient has no plan coverage for the product, no prescription coverage, or are in the process of appealing plan determination (during the appeal process). Patients with a government funded insurance plan are not eligible.

BRONCHITOL $0 Copay Assistance Program is available to patients with commercial insurance. Patients pay as low as $0 out-of-pocket costs toward their prescription up to a monthly maximum of $860. To obtain this benefit, patients must be enrolled in Arna Assist and utilize one of the specialty pharmacies in the network. Upon enrollment, the offer is valid for 12 months of copay assistance. Patients with primary enrollment in government-funded plans are not eligible for copay assistance.

Get savings and support with Arna Assist

Arna Assist is here to help your patients start, stay, and save on BRONCHITOL® (mannitol) inhalation powder

Eligible patients pay as little as $0 for their prescription with copay assistance, automatically applied when a prescription is sent to an in-network specialty pharmacy*

Enroll your eligible patients and take advantage of these support resources.

Two easy ways for eligible patients to get started with Arna Assist:

Arna Assist Terms and Conditions

*Co-Pay Assistance Program Eligibility and Details:

  • Patient must fill through a Specialty Pharmacy contracted with Arna Pharma to participate in the BRONCHITOL $0 Co-Pay Assistance Program. The list of participating pharmacies can be accessed by clicking here. The Co-Pay Assistance Program may be available for eligible patients when filling through a contracted Specialty Pharmacy – no enrollment is required.
  • Patient has commercial insurance and a valid prescription for a US Food and Drug Administration (FDA)-approved indication for BRONCHITOL. Click here to view Prescribing Information. A patient who receives health care benefits under any plan or program funded in whole or in part by federal or state governments including Medicare, Medicaid, TRICARE, Veterans Affairs (VA), State Prescription Assistance Plans (SPAPs) (other than health insurance for federal government employees) or any state health care program such as Medicaid, Children’s Health Insurance Program, programs funded under Maternal and Child Health Program or programs funded under Social Services Block Grant are not eligible for the Co-Pay Assistance Program. A patient covered under a commercial health plan purchased through a health insurance marketplace or exchange is not a Government Program Beneficiary even if the costs of such coverage are subsidized by the federal government.
  • Patient must be a resident of the United States or one of its territories.
  • Patient may elect to enroll in Arna Assist by clicking this link. Enrollment in Arna Assist is not required to participate in the Co-Pay Assistance Program.
  • Please refer to the full Terms and Conditions for all eligibility requirements.

Restrictions apply. Patients receiving Medicare, Medicaid, or that are participating in any other state or federally subsidized pharmacy benefit program are not eligible for the BRONCHITOL Patient Assistance Program but may be eligible for other non-financial components of the program. Please see full Terms and Conditions for additional eligibility requirements.

Arna Assist comprehensive services include :

Benefits Investigations

Financial assistance

One-on-one support

Important Safety Information

BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).

BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.

Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.

Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.

Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.

Please see Full Prescribing Information.

About BRONCHITOL® (mannitol) inhalation powder

BRONCHITOL is a prescription medicine that is used along with other therapies to improve lung function in people 18 years of age and older with cystic fibrosis (CF).

BRONCHITOL is only for adults who have passed the BRONCHITOL Tolerance Test (BTT). Your first dose of BRONCHITOL is given during the BTT by your healthcare provider and tests if BRONCHITOL is right for you. Your healthcare provider will use equipment to monitor you and have medicine ready if you have bronchospasm during the test. If you have bronchospasm during your BTT, then you should not be prescribed BRONCHITOL.

BRONCHITOL should not be used in children and adolescents. It is not known if BRONCHITOL is safe and effective in children under 18 years of age.